Patients with severe atopic dermatitis may get access to dupilumab within months following a recommendation for PBS listing by the Pharmaceutical Benefits Advisory Committee (PBAC) . At its March meeting the PBAC recommended the listing of dupilumab for the treatment of patients aged 12 years and older with severe atopic dermatitis who are inadequately controlled ...
Third time lucky for dupilumab with PBS listing recommendation in severe AD
By Michael Woodhead
29 Apr 2020